MeSH tree: C12.050.351.937.820.535.160
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association ...
Apr 8, 2024
0
84
Kidney cancer is one the most common cancers in the U.S., with over 81,000 new diagnoses in 2023 alone. Mayo Clinic sees a high volume of kidney cancer cases and is among the most experienced institutions in treating kidney ...
Apr 5, 2024
0
32
A combination of immunotherapy and targeted therapies show promise in managing metastatic renal cell carcinoma (RCC), the most common form of kidney cancer that makes up 90% of all cases. However, accurately predicting responses ...
Apr 5, 2024
0
65
Patients with primary cutaneous B-cell lymphomas (PCBCLs) have an increased risk for second primary malignancies (SPMs), according to a study published online March 19 in the Journal of the American Academy of Dermatology.
Apr 4, 2024
0
45
A new study from Karolinska Institutet discovered that blocking the MYC tumor protein in kidney cancer cells leads to an increase in fat droplets, which are associated with tumor growth. The study, published in Proceedings ...
Feb 19, 2024
0
57
Scientists have developed a new AI tool that maps the function of proteins in a cancerous tumor, enabling clinicians to decide how to target treatment in a more precise way.
Feb 9, 2024
0
44
For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the ...
Feb 1, 2024
0
41
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large ...
Jan 29, 2024
0
40
For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.
Jan 27, 2024
0
61
A new study led by Yale Cancer Center researchers at Yale School of Medicine has revealed a significant increase in patients starting immunotherapy within one month of death. Using a national clinical database, the researchers ...
Jan 4, 2024
0
75
